Fewer Pharma Layoffs as Job Postings Rise

Pharmaceutical industry employment trends shifted in the second quarter of 2026, with a marked reduction in workforce cuts and a simultaneous rise in job postings.

Headcount adjustments slow

Companies in the biopharma sector announced 26 headcount reductions in the second quarter, a 59% decrease from the 64 events recorded a year earlier. The total number of positions affected dropped 5% to 8,383 workers, according to data from BioSpace.

While large-scale layoffs continued at Takeda, Viatris, and BioNTech, the overall pace of reduction has eased compared to previous years. The Bureau of Labor Statistics reported that U.S. payroll employment in biotechnology R&D was 3.1% higher than in June of the prior year, and pharmaceutical and medicine manufacturing employment increased by 1.0%.

Corporate restructuring drove the majority of the 84 events described in the data, accounting for 25 occurrences and impacting 9,952 of the 14,681 positions listed. Pipeline reprioritization or strategic reviews ranked second by frequency with 20 events and 380 jobs, followed by site and manufacturing consolidation, which involved six events and 2,774 jobs.

Merger and acquisition integration and regulatory setbacks each appeared in eight announcements, signaling a continued focus on operational streamlining following major deals and shifting approval environments.

Despite fewer cuts, hiring activity picked up. BioSpace reported that biotechnology R&D job postings rose 42% year over year in June, with live postings across its platform increasing 15% in the second quarter.

Company-specific actions

Sanofi disclosed plans to cut 229 Blueprint employees in Cambridge following its $9.5 billion acquisition of Blueprint Medicines. Separations are scheduled from October 9, 2026, to June 25, 2027. Aardvark also reduced its staff after layoffs in June left the company with 28 employees and 27 consultants as of July 31.

Merck & Co. expanded its existing cost program by $2.5 billion, focusing on technology and simplification work across commercial, R&D, and manufacturing operations. Clinuvel is cutting 10% to 20% of its global workforce and moving its headquarters from Australia to New York at the start of 2027 to concentrate resources on U.S. regulatory engagement and commercialization.

Streamlining efforts are also evident at Pfizer, which added $2.5 billion to its cost program. GSK disclosed a three-year restructuring plan with global job cuts, while Amgen confirmed roughly 40 role eliminations tied to organizational changes.

Ensoma cut staff for the second time in under a year and paused work on all programs other than its lead asset, EN-374, while pursuing additional financing. Aurora deprioritized its lead phenylketonuria gene editing program, citing competition, and let go of several team members. Arpeggio decided in July to wind down operations after failing to separate the efficacy of its lead NRF2 degrader from an off-target liability.

Another company paused or ended most legacy Apellis preclinical programs and eliminated a small number of related research roles after the acquisition. Sangamo eliminated 51 roles and retained 77 employees while pursuing Chapter 11 asset sales to Eli Lilly and Astellas.

Regional and sector shifts

Restructuring plans often target specific geographic hubs. A New Jersey WARN notice disclosed 322 additional layoffs at Novartis’ East Hanover headquarters effective October 2. Pfizer implemented a three-day office requirement for remote R&D employees living more than 50 miles from Billerica. Up to 70 staff members may leave with severance if they decline relocation support.

Site closures also feature prominently. Novartis plans to close the Wehr production site. Gilead Sciences is closing the Seattle site of its stem cell therapy unit, which impacts approximately 55 employees. BioCryst will end internal discovery programs and close its Birmingham Discovery Center of Excellence.

Strategic pivots and wind-downs

Some firms are pausing operations or seeking new paths. After a planned merger with cancer imaging company Kuva Labs collapsed, Lisata cut about 72% of its full-time staff. The company sued Kuva for breach of the merger agreement, seeking damages and a $2 million termination fee. A drug developer shut down after a serious adverse event in a phase 2 alcohol-use-disorder trial.

Others are pivoting to specific markets. MindMaze Therapeutics disposed of Relief’s legacy Swiss operations, which employed about 25 people.

Financial pressures also drive change. Cutting half of staff and parting with several executives is necessary to stay nimble until 12-month data and an FDA BLA meeting. BioNTech plans to close JPT Peptide Technologies in Berlin as it concentrates resources on its late-stage oncology pipeline.